Critical Review: Assessment of Interferon-β Immunogenicity in Multiple Sclerosis

被引：11

作者：

Bendtzen, Klaus ^{[1
]}

机构：

[1] Rigshosp Univ Hosp, IIR, DK-2200 Copenhagen, Denmark

来源：

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH | 2010年 / 30卷 / 10期

关键词：

NEUTRALIZING ANTIBODIES; IFN-BETA; MS PATIENTS; AUTOANTIBODIES; BIOACTIVITY; ALPHA; QUANTIFICATION; CYTOKINES; BIOASSAY; THERAPY;

D O I：

10.1089/jir.2010.0091

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

This review discusses type I interferon (IFN) immunogenicity with focus on methods of detection of anti-IFN antibodies in patients treated with human recombinant IFN-beta. Pitfalls involved in the clinical use of various types of assays for binding antibodies and neutralizing antibodies against IFN-beta are presented, and the widely held distinction between binding antibodies and neutralizing antibodies is questioned both in terms of detection and clinical importance. The article also addresses important bioavailability and pharmacokinetic issues occurring with prolonged use of protein drugs. The rationale for individualized or personalized medicine, ie, optimizing therapies according to individual needs rather than using standardized trial-and-error regimens to all patients, is highlighted.

引用

页码：759 / 766

页数：8

共 47 条

[1] Detection of autoantibodies to cytokines [J].

Bendtzen, K ;

Hansen, MB ;

Ross, C ;

Svenson, M .

MOLECULAR BIOTECHNOLOGY, 2000, 14 (03) :251-261

[2] Anti-IFN BAb and NAb antibodies - A minireview [J].

Bendtzen, K .

NEUROLOGY, 2003, 61 (09) :S6-S10

[3] AUTOANTIBODIES TO CYTOKINES - FRIENDS OR FOES [J].

BENDTZEN, K ;

SVENSON, M ;

JONSSON, V ;

HIPPE, E .

IMMUNOLOGY TODAY, 1990, 11 (05) :167-169

[4] High-avidity autoantibodies to cytokines [J].

Bendtzen, K ;

Hansen, MB ;

Ross, C ;

Svenson, M .

IMMUNOLOGY TODAY, 1998, 19 (05) :209-211

[5]

Bendtzen K, 2007, AUTOANTIBODIES, 2ND EDITION, P299, DOI 10.1016/B978-044452763-9/50044-5

[6] Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies [J].

Bendtzen, Klaus ;

Ainsworth, Mark ;

Steenholdt, Casper ;

Thomsen, Ole Ostergaard ;

Brynskov, Jorn .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (07) :774-781

[7]

Bendtzen Klaus, 2008, V8, P127

[8] Implications of neutralising antibodies on therapeutic efficacy [J].

Bertototto, Antonio .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 277 :S29-S32

[9] Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. [J].

Casadevall, N ;

Nataf, J ;

Viron, B ;

Kolta, A ;

Kiladjian, J ;

Martin-Dupont, P ;

Michaud, P ;

Papo, T ;

Ugo, V ;

Teyssandier, I ;

Varet, B ;

Mayeux, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :469-475

[10] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

← 1 2 3 4 5 →